Pfizer ruins daily weight loss

Vizar He said on Monday that it would end its experimental development Daily pregnancy pills for weight loss After the patient suffered from the injury of the liver, which may be caused by the drug in the experiment.

A spokesman for Pfizer said in a statement that the patient had not faced any symptoms related to liver or side effects. They added that the patient’s liver enzymes were “recovering quickly” after they stopped taking birth control pills, which is the drug GLP-1 by orally called Danuglipron. The statement indicates that the patient’s liver enzymes were high, which often It indicates cell damage In the member and issue This has been linked to some other obesity medications.

The spokesman said that the case occurred in an experiment that rapidly increased the dose of the pill over a short period of time. Pfizer’s decision to stop the development of the drug came after “reviewing the overall information, including all the clinical data that has been created so far for Danuglipron and modern inputs from the organizers,” according to the statement.

“While we are disappointed to stop the development of Danuglipron, we are still committed to evaluating promising programs and progressing in them in an attempt to bring innovative new drugs to patients,” said Dr. Chris Busheov, the chief scientific employee in Phazer. He added that the company is still developing other weight loss drugs.

The advertisement adds to a series of setbacks in the company’s attempt to win a segment of the flourishing market for the GLP-1S, which mimics some bowel hormones to reduce appetite and regulate blood sugar. Pfizer is among the many drug makers that bring a more suitable weight loss to a weekly injection space, but it fails to competitors such as competitors like competitors such as Eli Lily and Novo Nordsk.

Some Wall Street analysts expect that the value of the GLP-1 industry will be more than $ 150 billion by the early 1930s. The GLP-1 can grow orally to $ 50 billion in this total, while the injection will explain the rest, according to Some analysts estimates.

This is not the first Pfizer collection with Danuglipron, specifically, also. Company to stop A copy twice a day of birth control pills in December 2023 after patients faced a problem in tolerance with the drug in the middle of the stage.

But it seems that Fayzer is confident in the shape once a day from Danuglipron in July, when he said it would be Start in studies In the second half of the year to assess multiple doses of birth control pills.

Despite its decision to cancel the medicine, Fayzer said on Monday that these studies have achieved major goals and confirmed a specific form and a dose of birth control pills with the possibility of providing “competitive effectiveness and tolerance” in late stage experiences.

The company also noticed that the rate High liver enzymes In people who took Danuglipron in line with approved GLP-1 drugs, which are based on a safety database that includes more than 1,400 patients who took Pfizer pills.

Pfizer canceled the different obesity pill once a day in June 2023 after the patients who took this medicine had higher liver enzyme levels in the mid -stage experience. Investors have been pessimistic about the company’s capabilities in the GLP-1 space since then.

However, Pfizer has Another experimental Obesity drugs are in their pipeline in the early stages of development that seem to be working differently from their eliminated treatments now. This includes an oral medicine that prevents another bowel hormone called GIPR, which entered the second stage of last year’s experiments, and GLP-1 orally once a day in the experiments of the first stage.

Pfizer believes that the drug targeting GIPR can be more effective and easier for patients to forgive. “There are a lot of applications for the GLP-1S.”

Danuglipron promotes weight weight loss by targeting the GLP-1, which is also how they injected weight loss in Novo Nordisk Wegovy and treat diabetes. Elie Lily’s injecting weight loss and diabetes are called Mounjaro Target GLP-1, but another intestinal hormone is also called GIP.

The only GLP-1 adopted by the Food and Drug Administration so far is the Novo Nordisk, which treats type 2 diabetes and occurs about $ 3.38 billion in sales In 2024.

The Pfizer advertisement comes on Monday, when the company regains its foot Restores the price of his share After the rapid decrease of her Covid work. Pfizer is betting on the cancer pipeline to achieve long -term growth, but he emphasized that obesity is a major axis.